{"DataElement":{"publicId":"6608084","version":"1","preferredName":"GD2 Antibody Prior Therapy Type","preferredDefinition":"Prior anti-GD2 therapy type","longName":"GD2_AB_PR_TX_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6608070","version":"1","preferredName":"GD2 Antibody Prior Therapy","preferredDefinition":"Any immunoglobulin that recognizes ganglioside GD2._Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","longName":"6608068v1.0:2223243v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6608086","version":"1","preferredName":"GD2 Antibody","preferredDefinition":"Any immunoglobulin that recognizes ganglioside GD2.","longName":"C129921","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GD2 Antibody","conceptCode":"C129921","definition":"Any immunoglobulin that recognizes ganglioside GD2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F22A0F3-4A37-4031-E053-F662850A738C","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2523432","version":"1","preferredName":"Prior Therapy","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.","longName":"C16124","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E77F88D-0ECE-5449-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-27","endDate":null,"createdBy":"UMLLOADER_DRUGSCREEN","dateCreated":"2006-09-27","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F20B261-7706-7569-E053-F662850AFB9D","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6608079","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6608079v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F23A959-B2D8-5440-E053-F662850AA413","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","deletedIndicator":"No"},{"value":"hu14.18-IL2","valueDescription":"Hu14.18-IL2 Fusion Protein","ValueMeaning":{"publicId":"6608081","version":"1","preferredName":"Hu14.18-IL2 Fusion Protein","longName":"6608081","preferredDefinition":"A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hu14.18-IL2 Fusion Protein EMD 273063","conceptCode":"C2509","definition":"A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 EMD 273063 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F23A959-B2E5-5440-E053-F662850AA413","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F23A959-B2FE-5440-E053-F662850AA413","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","deletedIndicator":"No"},{"value":"Dinutuximab (ch14.18)","valueDescription":"Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"3597790","version":"1","preferredName":"Monoclonal Antibody Ch14.18","longName":"3597790","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E763-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F23A959-B312-5440-E053-F662850AA413","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","deletedIndicator":"No"},{"value":"HU14.18K322A","valueDescription":"Anti-GD2 Monoclonal Antibody hu14.18K322A","ValueMeaning":{"publicId":"6608083","version":"1","preferredName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","longName":"6608083","preferredDefinition":"A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","conceptCode":"C80042","definition":"A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F23A959-B31F-5440-E053-F662850AA413","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F23A959-B338-5440-E053-F662850AA413","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","deletedIndicator":"No"},{"value":"3F8","valueDescription":"Monoclonal Antibody 3F8","ValueMeaning":{"publicId":"5076698","version":"1","preferredName":"Monoclonal Antibody 3F8","longName":"5076698","preferredDefinition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody 3F8","conceptCode":"C2370","definition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EC0E-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F23A959-B34C-5440-E053-F662850AA413","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F23A959-B2C4-5440-E053-F662850AA413","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please specify type of Anti-G","type":"Preferred Question Text","description":"Please specify type of Anti-GD2:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F216EDC-A3C8-313B-E053-F662850A55EF","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-10","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-11","changeDescription":"Curated for ANBL1821","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}